In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieve a durable complete response. Furthermore, ...

Recently, a research team led by Professor Zhengping Xu of Zhejiang University School of Medicine and its affiliated Sir Run Run Shaw Hospital published a paper in Science Bulletin titled ...

The researchers used lipid nanoparticles (LNPs) to deliver cyclic GMP-AMP (cGAMP) synthase (cGAS) mRNA to cancer cells. This results in production of the endogenous stimulator of interferon genes ...

Researchers designed CAR T cells that locally release VEGF-blocking molecules, weakening tumor defenses and boosting immune attack. The therapy slowed tumor growth and improved survival in cancer ...

For traditional cellular therapies like chimeric antigen receptor T-cell and NK-cell infusions, this "preconditioning" is vital to clear a biological path, removing endogenous cells that would ...

In recent years, we have come to appreciate that loss or dysfunction of insulin-producing islet beta cells underlies virtually all major forms of diabetes mellitus. In type 1 diabetes, beta cells ...